ImmunogenX reports net loss of $8.86M in 2023; auditor cites going concern doubts

GridAI Technologies Corp.

Net loss for 2023 was $8.86M, compared to $3.62M in 2022 and $1.66M in 2021.
Total assets of $4.1M vs. total liabilities of $18.33M as of Dec 31, 2023, resulting in stockholders' deficit of $14.23M.
Cash and cash equivalents only $251k as of Dec 31, 2023; auditor expressed substantial doubt about going concern.
Pre-revenue clinical-stage biotherapeutics company focused on celiac disease treatments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.